COLLHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Collegium Pharmaceutical, Inc. hold a median 12-month price target of $49 — +108.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 27 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Collegium Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (25): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on COLL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +108.8% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $50 |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $45 |
| 9 Sept 2026 | Truist Securities | Maintains | Buy | $58 → $49 |
| 9 Sept 2026 | Truist Securities | Maintains | Buy | — |
| 19 Aug 2026 | Barclays | Maintains | Overweight | $56 → $48 |
| 19 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Neutral | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Neutral | $45 → $43 |
| 6 Aug 2026 | Needham | Maintains | Buy | $56 → $46 |
| 6 Aug 2026 | Needham | Maintains | Buy | — |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $60 |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Needham | Reiterates | Buy | $54 → $56 |
| 19 Mar 2026 | Needham | Reiterates | Buy | — |
| 26 Feb 2026 | Needham | Maintains | Buy | — |
| 9 Jan 2026 | Barclays | Maintains | Overweight | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Jan 2026 | Needham | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
COLL appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Collegium Pharmaceutical, Inc. returned −34.4% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 40% of US stocks
Cheaper than 69% of US stocks
Cheaper than 37% of US stocks
Cheaper than 54% of US stocks
Higher than 43% of US stocks
Higher than 43% of US stocks
Higher than 68% of US stocks
Higher than 56% of US stocks
Higher than 62% of US stocks
Higher than 78% of US stocks
Higher than 80% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Collegium Pharmaceutical, Inc. has a market value of $748.8M and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $808.2M. The latest quarter grew 6.3% year on year.
Net income over the same four quarters: $47.9M, a 5.9% net margin.
Diluted earnings per share, trailing twelve months: $1.24.
Free cash flow in the twelve months to 30 June 2026: $328.3M.
Trailing P/E: 18.1×; forward P/E: 3.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Collegium Pharmaceutical, Inc. employs 357 people — $2.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Collegium Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Collegium Pharmaceutical announced it will report its third-quarter 2026 financial results before the market opens on November 5, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET after the release.
Why it matters — COLL watchers can note the scheduled date and time for the company’s upcoming quarterly results and related call.
Collegium said it will present seven studies across its ADHD portfolio at the AACAP and NEI Fall Congresses. The presentations include pediatric Phase 4 studies of AZSTARYS and real-world research on JORNAY PM in adults and its impact on caregivers.
Why it matters — The presentations provide updates on pediatric and real-world research involving two products in Collegium’s ADHD portfolio.
Zacks Investment Research compared Collegium Pharmaceutical and Daiichi Sankyo in a stock-value article focused on Medical - Drugs stocks. The excerpt identifies both companies as stocks investors may be familiar with.
Why it matters — The article places COLL in a value comparison with Daiichi Sankyo, but the excerpt provides no findings about relative value.
Seeking Alpha describes Collegium as a high-risk Buy following a sharp guidance cut and stock drop, arguing the market may be pricing in excessive pessimism. It highlights growth and patent protection for Jornay PM and AZSTARYS, alongside staged declines and differing patent risks across the pain portfolio.
Why it matters — COLL watchers may weigh the ADHD drugs’ growing contribution against generic pressure and patent-related risks in its pain franchise.
Zacks Investment Research reports that analysts’ consensus price target implies 111.4% upside potential for Collegium Pharmaceutical. It notes that this metric has limited empirical effectiveness, while rising earnings estimate revisions could indicate near-term upside.
Why it matters — COLL watchers may note the analyst-target estimate and the reported trend in earnings estimate revisions, alongside the caveat about the target metric’s effectiveness.
The 8 Wall Street analysts covering Collegium Pharmaceutical, Inc. have a median 12-month price target of $49, with estimates ranging from $43 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Collegium Pharmaceutical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Collegium Pharmaceutical, Inc. 72 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Collegium Pharmaceutical, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +108.8% from the last close, and Ticker Nerd's factor model ranks Collegium Pharmaceutical, Inc. 72 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Collegium Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $60 over the next 12 months.
Collegium Pharmaceutical, Inc. returned -34.4% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD).
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026". Collegium Pharmaceutical announced it will report its third-quarter 2026 financial results before the market opens on November 5, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET after the release.
Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.
CEO Mr. Vikram Karnani · 357 employees · United States · https://www.collegiumpharma.com
